Research analysts at B. Riley started coverage on shares of Catalyst Biosciences (NASDAQ:CBIO) in a report issued on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $19.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective indicates a potential upside of 151.99% from the company’s previous close.

Separately, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday, November 8th.

Catalyst Biosciences (NASDAQ:CBIO) traded up $0.39 during trading hours on Friday, hitting $7.54. 887,443 shares of the stock were exchanged, compared to its average volume of 453,393. Catalyst Biosciences has a 12 month low of $3.11 and a 12 month high of $21.30.

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Catalyst Biosciences in the second quarter worth $107,000. Vanguard Group Inc. grew its stake in shares of Catalyst Biosciences by 294.1% in the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 32,621 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Catalyst Biosciences in the second quarter worth $103,000. Dimensional Fund Advisors LP acquired a new stake in shares of Catalyst Biosciences in the second quarter worth $372,000. Finally, Zacks Investment Management acquired a new stake in shares of Catalyst Biosciences in the second quarter worth $147,000. 31.47% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Catalyst Biosciences (CBIO) Coverage Initiated at B. Riley” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/08/catalyst-biosciences-cbio-coverage-initiated-at-b-riley.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.